Codexis (CDXS) risk factors
Item 1A of every Codexis, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors44 risks5 new4 dropped7 reworded
Accumulated deficit reached $606.8 million after a $44.0 million net loss in 2025. Manufacturing relies heavily on specific third-party CMOs abroad. Concentration of revenue remains high at 51% from key customers.
Filed Mar 11, 2026 - FY2024 10-K risk factors43 risks
Codexis faces significant ongoing net losses with an accumulated deficit of $562.8 million as of December 31, 2024. Revenue is heavily concentrated, with customers contributing 10% or more accounting for 51% of total revenue in 2024. The company relies heavily on unproven novel technologies like the ECO Synthesis manufacturing platform for enzymatic nucleic acid synthesis.
Filed Feb 27, 2025